Need help finding what you are looking for?
Contact Us
PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1189407
PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1189407
Latin America G-CSF PEG-G-CSF Market - Industry Trends and Forecast to 2030
PUBLISHED:
PAGES: 248 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Latin America G-CSF/ PEG-G-CSF market is projected to register a substantial CAGR of 5.9% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Latin America G-CSF/PEG-G-CSF Market, By Indication (Neutropenia, Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Harmony Deficiency and Others), Dosage (Mono and Combination), Route Of Administration (Intravenous, Subcuetaneous), Packaging (Single Use Vials and Pre Filled Syringes), End User (Hospitals and Clinics, Research and Academic Institutes, Ambulatory Surgical Centers and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others), Country (Mexico, Columbia, Brazil, Argentina, Chile, Peru, Ecuador, Rest of LATAM) Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the Latin America G-CSF/PEG-G-CSF market are:
Growing incidences of blood cancers and cancer diseases
Increasing cases of febrile neutropenia
Market Players:
The key market players operating in the Latin America G-CSF/PEG-G-CSF market are listed below:
Lupin
Intas Pharmaceuticals Ltd.
BIOSIDUS
Kashiv BioSciences, LLC.
STADA Arzneimittel AG
USV Private Limited
Viatris Inc.
Fresenius Kabi AG
Amgen Inc.
Pfizer Inc.
Sandoz International GmbH
Apotex Inc.
Cadila Pharmaceuticals
Dr. Reddy's Laboratories Ltd.
Amneal Pharmaceuticals LLC.
Coherus BioSciences
Accord Healthcare
NAPP PHARMACEUTICALS LIMITED.
Intas Pharmaceuticals Ltd.
Mundipharma International
Teva Pharmaceutical Industries Ltd.
Spectrum Pharmaceuticals, Inc.
Kyowa Kirin Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
TABLE OF CONTENTS
1 INTRODUCTION 50
- 1.1 OBJECTIVES OF THE STUDY 50
- 1.2 MARKET DEFINITION 50
- 1.3 OVERVIEW OF LATIN AMERICA G-CSF / PEG-G-CSF MARKET 50
- 1.4 LIMITATIONS 52
- 1.5 MARKETS COVERED 52
2 MARKET SEGMENTATION 55
- 2.1 MARKETS COVERED 55
- 2.2 GEOGRAPHICAL SCOPE 56
- 2.3 YEARS CONSIDERED FOR THE STUDY 57
- 2.4 CURRENCY AND PRICING 57
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
- 2.6 MULTIVARIATE MODELLING 61
- 2.7 TYPE LIFELINE CURVE 61
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
- 2.9 DBMR MARKET POSITION GRID 63
- 2.10 MARKET END USER COVERAGE GRID 64
- 2.11 VENDOR SHARE ANALYSIS 65
- 2.12 SECONDARY SOURCES 66
- 2.13 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 70
- 4.1 PESTEL ANALYSIS 71
- 4.2 PORTER'S FIVE FORCES 72
- 4.3 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 73
- 4.4 LATIN AMERICA G-CSF / PEG-G-CSF MARKET 74
- 4.5 STRATEGIES TO THE ENTER THE MARKET 74
- 4.5.1 JOINT VENTURE (PARTNERSHIPS): 74
- 4.5.2 ACQUISITION: 74
- 4.5.3 LINE EXPANSION VIA COLLABORATION: 74
- 4.5.4 PRODUCT APPROVAL: 75
- 4.5.5 PRODUCT LAUNCH: 75
- 4.5.6 GEOGRAPHIC EXPANSION: 75
- 4.5.7 COST LEADERSHIP: 76
- 4.5.8 PRODUCT DEVELOPMENT: 76
- 4.6 LATIN AMERICA G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 77
- 4.6.1 PATENT ANALYSIS 77
- 4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 78
- 4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 78
- 4.6.4 THERAPEUTIC ASSESSMENT 78
- 4.6.5 KEY PRICING STRATEGIES 79
- 4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 79
- 4.6.7 CONCLUSION 79
- 4.7 PIPELINE ANALYSIS FOR LATIN AMERICA G-CSF / PEG-G-CSF MARKET 80
5 EPIDEMIOLOGY 81
6 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: REGULATIONS 84
7 MARKET OVERVIEW 87
- 7.1 DRIVERS 89
- 7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 89
- 7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 90
- 7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 91
- 7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 92
- 7.2 RESTRAIN 93
- 7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 93
- 7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 94
- 7.3 OPPORTUNITIES 95
- 7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 95
- 7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 95
- 7.4 CHALLENGES 96
- 7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 96
- 7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 96
8 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION 97
- 8.1 OVERVIEW 98
- 8.2 NEUTROPENIA 102
- 8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 103
- 8.2.2 SEVERE CHRONIC NEUTROPENIA 103
- 8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 103
- 8.2.4 NEUTROPENIA IN HIV PATIENTS 103
- 8.2.5 CLOZAPINE INDUCED NEUTROPENIA 103
- 8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 103
- 8.2.7 CONGENITAL NEUTROPENIA 103
- 8.3 ONCOLOGY 104
- 8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 104
- 8.3.2 OTHERS 105
- 8.4 CHRONIC AND AUTO IMMUNE DISEASES 105
- 8.5 BLOOD DISORDERS 105
- 8.6 GROWTH HORMONE DEFICIENCY 106
- 8.7 OTHERS 107
9 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 108
- 9.1 OVERVIEW 109
- 9.2 MONO 112
- 9.3 COMBINATION 113
10 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 114
- 10.1 OVERVIEW 115
- 10.2 SUBCUTANEOUS 118
- 10.3 INTRAVENOUS 119
11 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 120
- 11.1 OVERVIEW 121
- 11.2 PRE FILLED SYRINGES 124
- 11.3 SINGLE USE VIALS 125
12 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY END USER 126
- 12.1 OVERVIEW 127
- 12.2 HOSPITALS AND CLINICS 130
- 12.3 RESEARCH & ACADEMIC INSTITUTES 130
- 12.4 AMBULATORY SURGICAL CENTERS 131
- 12.5 OTHERS 132
13 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 133
- 13.1 OVERVIEW 134
- 13.2 HOSPITALS PHARMACY 137
- 13.3 RETAIL PHARMACY 137
- 13.4 ONLINE PHARMACY 138
- 13.5 OTHERS 139
14 LATIN AMERICA G-CSF/PEG-G-CSF MARKET, BY REGION 140
- 14.1 LATIN AMERICA 141
- 14.1.1 MEXICO 147
- 14.1.2 COLUMBIA 155
- 14.1.3 BRAZIL 162
- 14.1.4 ARGENTINA 170
- 14.1.5 CHILE 180
- 14.1.6 PERU 187
- 14.1.7 ECUADOR 194
15 LATIN AMERICA G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 202
- 15.1 COMPANY SHARE ANALYSIS: LATIN AMERICA 202
16 SWOT ANALYSIS 203
17 COMPANY PROFILE 204
- 17.1 PFIZER INC. 204
- 17.1.1 COMPANY SNAPSHOT 204
- 17.1.2 REVENUE ANALYSIS 205
- 17.1.3 COMPANY SHARE ANALYSIS 205
- 17.1.4 PRODUCT PORTFOLIO 206
- 17.1.5 RECENT DEVELOPMENTS 206
- 17.2 VIATRIS INC. 207
- 17.2.1 COMPANY SNAPSHOT 207
- 17.2.2 REVENUE ANALYSIS 207
- 17.2.3 COMPANY SHARE ANALYSIS 208
- 17.2.4 PRODUCT PORTFOLIO 208
- 17.2.5 RECENT DEVELOPMENT 208
- 17.3 AMGEN INC. 209
- 17.3.1 COMPANY SNAPSHOT 209
- 17.3.2 REVENUE ANALYSIS 209
- 17.3.3 COMPANY SHARE ANALYSIS 210
- 17.3.4 PRODUCT PORTFOLIO 210
- 17.3.5 RECENT DEVELOPMENTS 210
- 17.4 STADA ARZENEIMITTEL AG 212
- 17.4.1 COMPANY SNAPSHOT 212
- 17.4.2 COMPANY SHARE ANALYSIS 212
- 17.4.3 PRODUCT PORTFOLIO 213
- 17.4.4 RECENT DEVELOPMENT 213
- 17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 214
- 17.5.1 COMPANY SNAPSHOT 214
- 17.5.2 REVENUE ANALYSIS 214
- 17.5.3 COMPANY SHARE ANALYSIS 215
- 17.5.4 PRODUCT PORTFOLIO 215
- 17.5.5 RECENT DEVELOPMENTS 215
- 17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 216
- 17.6.1 COMPANY SNAPSHOT 216
- 17.6.2 PRODUCT PORTFOLIO 216
- 17.6.3 RECENT DEVELOPMENTS 216
- 17.7 ACCORD HEALTHCARE 217
- 17.7.1 COMPANY SNAPSHOT 217
- 17.7.2 PRODUCT PORTFOLIO 217
- 17.7.3 RECENT DEVELOPMENTS 217
- 17.8 AMNEAL PHARMACEUTICALS LLC. 218
- 17.8.1 COMPANY SNAPSHOT 218
- 17.8.2 REVENUE ANALYSIS 218
- 17.8.3 PRODUCT PORTFOLIO 219
- 17.8.4 RECENT DEVELOPMENTS 219
- 17.9 APOTEX INC. 220
- 17.9.1 COMPANY SNAPSHOT 220
- 17.9.2 PRODUCT PORTFOLIO 220
- 17.9.3 RECENT DEVELOPMENT 220
- 17.10 BIOCON 221
- 17.10.1 COMPANY SNAPSHOT 221
- 17.10.2 REVENUE ANALYSIS 221
- 17.10.3 PRODUCT PORTFOLIO 222
- 17.10.4 RECENT DEVELOPMENT 222
- 17.11 BIO SIDUS 223
- 17.11.1 COMPANY SNAPSHOT 223
- 17.11.2 PRODUCT PORTFOLIO 223
- 17.11.3 RECENT DEVELOPMENTS 223
- 17.12 CADILA PHARMACEUTICALS 224
- 17.12.1 COMPANY SNAPSHOT 224
- 17.12.2 PRODUCT PORTFOLIO 224
- 17.12.3 RECENT DEVELOPMENTS 224
- 17.13 COHERUS BIOSCIENCES 225
- 17.13.1 COMPANY SNAPSHOT 225
- 17.13.2 REVENUE ANALYSIS 225
- 17.13.3 PRODUCT PORTFOLIO 226
- 17.13.4 RECENT DEVELOPMENT 226
- 17.14 DR. REDDY'S LABORATORIES LTD 227
- 17.14.1 COMPANY SNAPSHOT 227
- 17.14.2 REVENUE ANALYSIS 227
- 17.14.3 PRODUCT PORTFOLIO 228
- 17.14.4 RECENT DEVELOPMENTS 228
- 17.15 FRESENIUS KABI AG 229
- 17.15.1 COMPANY SNAPSHOT 229
- 17.15.2 PRODUCT PORTFOLIO 229
- 17.15.3 RECENT DEVELOPMENT 229
- 17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 230
- 17.16.1 COMPANY SNAPSHOT 230
- 17.16.2 PRODUCT PORTFOLIO 230
- 17.16.3 RECENT DEVELOPMENTS 230
- 17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 231
- 17.17.1 COMPANY SNAPSHOT 231
- 17.17.2 PRODUCT PORTFOLIO 231
- 17.17.3 RECENT DEVELOPMENTS 231
- 17.18 INTAS PHARMACEUTICALS LTD. 232
- 17.18.1 COMPANY SNAPSHOT 232
- 17.18.2 PRODUCT PORTFOLIO 232
- 17.18.3 RECENT DEVELOPMENT 232
- 17.19 KASHIV BIOSCIENCES, LLC. 233
- 17.19.1 COMPANY SNAPSHOT 233
- 17.19.2 PRODUCT PORTFOLIO 233
- 17.19.3 RECENT DEVELOPMENT 233
- 17.20 KYOWA KIRIN CO., LTD. 234
- 17.20.1 COMPANY SNAPSHOT 234
- 17.20.2 REVENUE ANALYSIS 234
- 17.20.3 PRODUCT PORTFOLIO 235
- 17.20.4 RECENT DEVELOPMENT 235
- 17.21 LUPIN 236
- 17.21.1 COMPANY SNAPSHOT 236
- 17.21.2 REVENUE ANALYSIS 236
- 17.21.3 PRODUCT PORTFOLIO 237
- 17.21.4 RECENT DEVELOPMENT 237
- 17.22 MUNDIPHARMA INTERNATIONAL. 238
- 17.22.1 COMPANY SNAPSHOT 238
- 17.22.2 PRODUCT PORTFOLIO 238
- 17.22.3 RECENT DEVELOPMENT 238
- 17.23 NAPP PHARMACEUTICALS LIMITED 239
- 17.23.1 COMPANY SNAPSHOT 239
- 17.23.2 PRODUCT PORTFOLIO 239
- 17.23.3 RECENT DEVELOPMENT 239
- 17.24 RELIANCE LIFE SCIENCES 240
- 17.24.1 COMPANY SNAPSHOT 240
- 17.24.2 PRODUCT PORTFOLIO 240
- 17.24.3 RECENT DEVELOPMENTS 240
- 17.25 SANDOZ INTERNATIONAL GMBH 241
- 17.25.1 COMPANY SNAPSHOT 241
- 17.25.2 REVENUE ANALYSIS 241
- 17.25.3 PRODUCT PORTFOLIO 242
- 17.25.4 RECENT DEVELOPMENTS 242
- 17.26 SPECTRUM PHARMACEUTICALS, INC. 243
- 17.26.1 COMPANY SNAPSHOT 243
- 17.26.2 PRODUCT PORTFOLIO 243
- 17.26.3 RECENT DEVELOPMENT 243
- 17.27 USV PRIVATE LIMITED 244
- 17.27.1 COMPANY SNAPSHOT 244
- 17.27.2 PRODUCT PORTFOLIO 244
- 17.27.3 RECENT DEVELOPMENTS 244
18 QUESTIONNAIRE 245
19 RELATED REPORTS 248
LIST OF TABLES
- TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 59
- TABLE 2 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 76
- TABLE 3 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 77
- TABLE 4 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 77
- TABLE 5 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 79
- TABLE 6 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 79
- TABLE 7 LATIN AMERICA CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80
- TABLE 8 LATIN AMERICA BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81
- TABLE 9 LATIN AMERICA GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81
- TABLE 10 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 82
- TABLE 11 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 86
- TABLE 12 LATIN AMERICA MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 87
- TABLE 13 LATIN AMERICA COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 88
- TABLE 14 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 92
- TABLE 15 LATIN AMERICA SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 93
- TABLE 16 LATIN AMERICA INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 94
- TABLE 17 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 98
- TABLE 18 LATIN AMERICA PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 99
- TABLE 19 LATIN AMERICA SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 100
- TABLE 20 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 104
- TABLE 21 LATIN AMERICA HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 105
- TABLE 22 LATIN AMERICA RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 106
- TABLE 23 LATIN AMERICA AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 106
- TABLE 24 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 107
- TABLE 25 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 111
- TABLE 26 LATIN AMERICA HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 112
- TABLE 27 LATIN AMERICA RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 113
- TABLE 28 LATIN AMERICA ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 113
- TABLE 29 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 114
- TABLE 30 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 119
- TABLE 31 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 119
- TABLE 32 LATAM G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 119
- TABLE 33 LATAM G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119
- TABLE 34 LATAM NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 120
- TABLE 35 LATAM ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 120
- TABLE 36 LATAM G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 120
- TABLE 37 LATAM G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 121
- TABLE 38 LATAM G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 121
- TABLE 39 LATAM G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 121
- TABLE 40 LATAM G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 121
- TABLE 41 MEXICO G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 122
- TABLE 42 MEXICO NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 122
- TABLE 43 MEXICO ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 123
- TABLE 44 MEXICO G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 123
- TABLE 45 MEXICO MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123
- TABLE 46 MEXICO G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 123
- TABLE 47 MEXICO SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
- TABLE 48 MEXICO INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
- TABLE 49 MEXICO G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 124
- TABLE 50 MEXICO PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
- TABLE 51 MEXICO G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 125
- TABLE 52 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125
- TABLE 53 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 125
- TABLE 54 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125
- TABLE 55 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
- TABLE 56 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126
- TABLE 57 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 126
- TABLE 58 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
- TABLE 59 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126
- TABLE 60 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127
- TABLE 61 MEXICO G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 127
- TABLE 62 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
- TABLE 63 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 127
- TABLE 64 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127
- TABLE 65 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 128
- TABLE 66 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128
- TABLE 67 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128
- TABLE 68 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 128
- TABLE 69 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 129
- TABLE 70 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 129
- TABLE 71 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 130
- TABLE 72 COLUMBIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 130
- TABLE 73 COLUMBIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 131
- TABLE 74 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 131
- TABLE 75 COLUMBIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131
- TABLE 76 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 131
- TABLE 77 COLUMBIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132
- TABLE 78 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 132
- TABLE 79 COLUMBIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132
- TABLE 80 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 132
- TABLE 81 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
- TABLE 82 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133
- TABLE 83 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133
- TABLE 84 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
- TABLE 85 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133
- TABLE 86 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134
- TABLE 87 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134
- TABLE 88 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134
- TABLE 89 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134
- TABLE 90 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 134
- TABLE 91 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135
- TABLE 92 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 135
- TABLE 93 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 135
- TABLE 94 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135
- TABLE 95 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 136
- TABLE 96 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 136
- TABLE 97 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 136
- TABLE 98 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 136
- TABLE 99 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 136
- TABLE 100 BRAZIL G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 137
- TABLE 101 BRAZIL NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 137
- TABLE 102 BRAZIL ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 138
- TABLE 103 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 138
- TABLE 104 BRAZIL MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138
- TABLE 105 BRAZIL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 138
- TABLE 106 BRAZIL SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139
- TABLE 107 BRAZIL G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 139
- TABLE 108 BRAZIL PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139
- TABLE 109 BRAZIL G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 139
- TABLE 110 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140
- TABLE 111 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140
- TABLE 112 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140
- TABLE 113 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140
- TABLE 114 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141
- TABLE 115 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 141
- TABLE 116 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 141
- TABLE 117 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141
- TABLE 118 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 142
- TABLE 119 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 142
- TABLE 120 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142
- TABLE 121 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 142
- TABLE 122 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 143
- TABLE 123 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 143
- TABLE 124 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 143
- TABLE 125 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 143
- TABLE 126 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 144
- TABLE 127 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 144
- TABLE 128 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 144
- TABLE 129 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 145
- TABLE 130 ARGENTINA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 145
- TABLE 131 ARGENTINA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 146
- TABLE 132 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 146
- TABLE 133 ARGENTINA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146
- TABLE 134 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 146
- TABLE 135 ARGENTINA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 147
- TABLE 136 ARGENTINA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 147
- TABLE 137 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 147
- TABLE 138 ARGENTINA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 147
- TABLE 139 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 148
- TABLE 140 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 148
- TABLE 141 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 148
- TABLE 142 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 149
- TABLE 143 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 149
- TABLE 144 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 149
- TABLE 145 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 150
- TABLE 146 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 150
- TABLE 147 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 150
- TABLE 148 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 151
- TABLE 149 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 151
- TABLE 150 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 151
- TABLE 151 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 152
- TABLE 152 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 152
- TABLE 153 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 152
- TABLE 154 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 153
- TABLE 155 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 153
- TABLE 156 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 153
- TABLE 157 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 154
- TABLE 158 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 154
- TABLE 159 CHILE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 155
- TABLE 160 CHILE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 155
- TABLE 161 CHILE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 156
- TABLE 162 CHILE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 156
- TABLE 163 CHILE MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 156
- TABLE 164 CHILE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 156
- TABLE 165 CHILE SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 156
- TABLE 166 CHILE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 157
- TABLE 167 CHILE PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 157
- TABLE 168 CHILE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 157
- TABLE 169 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 157
- TABLE 170 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 158
- TABLE 171 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 158
- TABLE 172 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 158
- TABLE 173 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 158
- TABLE 174 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 158
- TABLE 175 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 159
- TABLE 176 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 159
- TABLE 177 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 159
- TABLE 178 CHILE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 159
- TABLE 179 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 160
- TABLE 180 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 160
- TABLE 181 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 160
- TABLE 182 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 160
- TABLE 183 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 160
- TABLE 184 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 161
- TABLE 185 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 161
- TABLE 186 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 161
- TABLE 187 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 161
- TABLE 188 PERU G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 162
- TABLE 189 PERU NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 162
- TABLE 190 PERU ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 163
- TABLE 191 PERU G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 163
- TABLE 192 PERU MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 163
- TABLE 193 PERU G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 163
- TABLE 194 PERU SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 164
- TABLE 195 PERU INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 164
- TABLE 196 PERU G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 164
- TABLE 197 PERU PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 164
- TABLE 198 PERU SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 164
- TABLE 199 PERU G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 165
- TABLE 200 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 165
- TABLE 201 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 165
- TABLE 202 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 165
- TABLE 203 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 165
- TABLE 204 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 166
- TABLE 205 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 166
- TABLE 206 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 166
- TABLE 207 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 166
- TABLE 208 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 166
- TABLE 209 PERU G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 166
- TABLE 210 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 167
- TABLE 211 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 167
- TABLE 212 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 167
- TABLE 213 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 167
- TABLE 214 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 167
- TABLE 215 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 168
- TABLE 216 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 168
- TABLE 217 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 168
- TABLE 218 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 168
- TABLE 219 ECUADOR G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 169
- TABLE 220 ECUADOR NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 169
- TABLE 221 ECUADOR ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 170
- TABLE 222 ECUADOR G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 170
- TABLE 223 ECUADOR MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 170
- TABLE 224 ECUADOR G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 170
- TABLE 225 ECUADOR SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 171
- TABLE 226 ECUADOR INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 171
- TABLE 227 ECUADOR G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 171
- TABLE 228 ECUADOR PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 171
- TABLE 229 ECUADOR G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 172
- TABLE 230 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 172
- TABLE 231 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 172
- TABLE 232 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 172
- TABLE 233 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 173
- TABLE 234 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 173
- TABLE 235 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 173
- TABLE 236 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 173
- TABLE 237 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 174
- TABLE 238 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 174
- TABLE 239 ECUADOR G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 174
- TABLE 240 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 174
- TABLE 241 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 175
- TABLE 242 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 175
- TABLE 243 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 175
- TABLE 244 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 175
- TABLE 245 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 175
- TABLE 246 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 176
- TABLE 247 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 176
- TABLE 248 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 176
LIST OF FIGURES
- FIGURE 1 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: SEGMENTATION 29
- FIGURE 2 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION 32
- FIGURE 3 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS 33
- FIGURE 4 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: LATIN AMERICA VS REGIONAL MARKET ANALYSIS 34
- FIGURE 5 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS 34
- FIGURE 6 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS 36
- FIGURE 7 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID 37
- FIGURE 8 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID 38
- FIGURE 9 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS 39
- FIGURE 10 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: SEGMENTATION 43
- FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030 44
- FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET IN 2023 & 2030 44
- FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET 62
- FIGURE 14 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022 73
- FIGURE 15 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION) 74
- FIGURE 16 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029) 74
- FIGURE 17 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE 75
- FIGURE 18 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022 83
- FIGURE 19 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION) 84
- FIGURE 20 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030) 84
- FIGURE 21 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE 85
- FIGURE 22 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022 89
- FIGURE 23 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 90
- FIGURE 24 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 90
- FIGURE 25 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 91
- FIGURE 26 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022 95
- FIGURE 27 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION) 96
- FIGURE 28 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030) 96
- FIGURE 29 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE 97
- FIGURE 30 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022 101
- FIGURE 31 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION) 102
- FIGURE 32 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030) 102
- FIGURE 33 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE 103
- FIGURE 34 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022 108
- FIGURE 35 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 109
- FIGURE 36 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 109
- FIGURE 37 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 110
- FIGURE 38 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022) 115
- FIGURE 39 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022) 116
- FIGURE 40 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 116
- FIGURE 41 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 117
- FIGURE 42 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030) 117
- FIGURE 43 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%) 176
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.